SP001 IBI355 Updated Jul 14
SP001 is a new pipeline asset for Spero, announced alongside a $105M non-dilutive royalty financing from Utebzi sales. Watch for the Phase 2 initiation in IgG4-RD (Q2 2027) as the next catalyst. The stock may re-rate on execution towards Phase 2 start, but the $1.1B milestone burden relative to Spero's ~$126M market cap is a significant overhang. Monitor Innovent's Phase 2 SjD data in China (early 2027) as a read-through for the mechanism.
- SP001 is a third-generation Fc-silent anti-CD40L antibody, a clinically validated mechanism with built-in safety improvements over first-gen drugs that caused thrombotic side effects. Phase 1 data in healthy volunteers and Sjögren's patients have been presented at EULAR 2026, de-risking the asset.
- Spero simultaneously raised $105M via non-dilutive Healthcare Royalty financing backed by recently approved Utebzi (tebipenem) royalties, providing cash to fund SP001 development without immediate shareholder dilution.
- IgG4-related disease is a rare autoimmune indication with high unmet need, a successful development path could command orphan-drug pricing and a focused commercial strategy.
- SP001 is still preclinical for IgG4-RD, the lead Spero indication. Only Phase 1 healthy-volunteer and Sjögren's data exist, efficacy in IgG4-RD is unproven. Phase 2 may fail or be delayed.
- The deal carries up to ~$1.1B in milestone obligations to Innovent, a massive liability relative to Spero's ~$126M market cap. Even modest success triggers payments that could strain the balance sheet.
- Competition is mounting: inebilizumab (anti-CD19) recently showed an 87% reduction in IgG4-RD flares in Phase 3, and other anti-CD40L antibodies (dapirolizumab, amlitelimab) are in development for overlapping indications.